

IBA and RaySearch showcase the first Online Adaptive Proton Therapy workflow at ESTRO

Louvain-la-Neuve, Belgium, and Stockholm, Sweden, April 16, 2018 – IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, and RaySearch Laboratories, the global leader in treatment planning software, will demonstrate at the ESTRO congress how they will optimize patient treatment by offering the first online adaptive proton therapy workflow.

IBA and RaySearch will present their full size demonstration including the RayCare®* oncology information system, the RayTreatment workflow and treatment planning system, the AdaPT Insight imaging platform and the AdaPT Deliver treatment delivery. In an online adaptive workflow, daily cone beam CT images are used and matched to the planning CT of an individual patient.

This allows to automatically suggest to the care team an adapted treatment plan which takes into

This allows to automatically suggest to the care team an adapted treatment plan which takes into account the most up to date patient's anatomy. This workflow offers more accurate treatment plans as well as faster plan adaptation to the benefit of patients.

Frederic Genin, Head of Product Management at IBA, commented: "The combination of IBA's cutting-edge Cone Beam Imaging solutions with the treatment planning and treatment workflow solutions from RaySearch enable our future clinical partners to make Online Adaptive Proton Therapy a reality. We are very excited to see how these advanced functionalities can be beneficial to the patients around the world."

Björn Hårdemark, Deputy Chief Executive Officer of RaySearch, added: "The treatment planning technologies necessary for adaptive re-planning have been available in RayStation® for many years now. With the introduction of RayCare, we also enabled the workflow components for offline adaptive treatments. To make online adaptive treatments possible, a tight integration to the delivery systems is necessary. The strategic alliance between IBA and RaySearch has provided the perfect circumstances to achieve this. The successful integration shows the strength of a collaborative approach."

The live demo of the first online adaptive Proton Therapy workflow will be demonstrated on IBA booth #1400 during the European Society for Radiotherapy & Oncology (ESTRO) annual congress that will take place in Barcelona, Spain, from April 20th to 24th.



Press Release



About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has launched the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch. RaySearch's software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

More information about RaySearch is available at http://www.raysearchlabs.com

* Subject to regulatory clearance in some markets.

For further information, please contact:

IBA

Aymeric Harmant
Global Marketing Director
+32 10 201 287
global.marketing@iba-group.com

RaySearch Johan Löf President and CEO, RaySearch Laboratories AB (publ) +46 (0)8-510 530 00 johan.lof@raysearchlabs.com

